Press Release

Updates and news NEWS "The communication tools between cells can be used as therapeutics."

Updates and news NEWS Congratulations on the second foundation anniversary of SHIFTBIO INC.

Updates and news NEWS Dr. In-San Kim, a co-founder of SHIFTBIO INC., has been appointed as a fellow researcher at the Korea Institute of Science and Technology (KIST)

Updates and news NEWS "Why to use EVs as the CD47 blockade?"

Updates and news NEWS SHIFTBIO INC. announced the detailed realization plan upon The SBI-102 and the Intrinsic Nanovesicle-based platform technology

Updates and news NEWS SHIFTBIO INC. and RoosterBio had a valuable discussion on the large-scale production process development of SHIFTBIO INC’s main pipeline, SBI-102, along with innovative business models

Updates and news NEWS Dr. Gi-Hoon Nam, Co-Founder of SHIFTBIO INC, has joined as a panelist at the 23rd World Knowledge Forum

Updates and news NEWS “SHIFTBIO INC., a company that puts the armor on the avatar of cells”

Updates and news NEWS SHIFTBIO INC. attended the GLOBAL INVESTMENT SUMMIT 2022

Updates and news NEWS Korea’s leading media group, JoongAng News interviewed SHIFTBIO

Updates and news NEWS Thomas M. Roberts and Kenneth W. Witwer became the first two official ShiftBio Scientific Advisory Board members!

Updates and news NEWS ShiftBio Partners with RoosterBio Inc. to Develop SBI-102 for Rare Diseases and Cancer

Updates and news NEWS In-San Kim, MD, Ph.D. featured on the International Society for Extracellular Vesicles (ISEV) eNEWs